Abstract
Purpose: To investigate the efficacy and tolerability of CMO (cerasomol- cis -9-cetyl myristoleate) in the treatment of fibromyalgia. Design: Open study: 21 days' treatment following a 7-day baseline without treatment. Materials and Methods: Thirteen adult patients with fibromyalgia. Following a 7-day pre-treatment baseline, patients were treated with a mixture of CMO + sea cucumber and shark cartilage extracts. All treatments were administered orally. Patients kept daily diary cards recording the severity of generalized pain, fatigue and sleep disturbance (scale 0-4). A symptom profile was made using an 84-point questionnaire. Adverse events were recorded. Results: Ten patients completed the study. One subject did not record baseline symptoms. Two patients had to discontinue treatment because of adverse effects. One had severe indigestion and the other developed muscle spasms and a skin rash. The mean (SD) scores for the severity of pain, fatigue, and sleep disturbance during the baseline were 2.63 (0.55...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Nutritional & Environmental Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
